National surveillance of emergency department visits for outpatient adverse drug events.
about
Pharmacogenetics and anaesthesia: the value of genetic profilingPredicting adverse drug reactions in older adults; a systematic review of the risk prediction modelsPharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonStroke genetics: prospects for personalized medicineChanges in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011Emergency department visits for antibiotic-associated adverse eventsAdverse drug reactions related hospital admissions in persons aged 60 years and over, The Netherlands, 1981-2007: less rapid increase, different drugsDevelopment and validation of a risk model for predicting adverse drug reactions in older people during hospital stay: Brighton Adverse Drug Reactions Risk (BADRI) modelDictionary construction and identification of possible adverse drug events in Danish clinical narrative textElectronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.Warfarin genotyping with hybridization-induced aggregation on a poly(ethylene terephthalate) microdevice.Can older people remember medication reminders presented using synthetic speech?Emergency department visits for antiviral adverse events during the 2009 H1N1 influenza pandemic.Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005.Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.Development of an instrument to assess the impact of an enhanced experiential model on pharmacy students' learning opportunities, skills and attitudes: a retrospective comparative-experimentalist study.A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients.Preventing the preventable: reducing rehospitalizations through coordinated, patient-centered discharge processesIntegration of genetic, clinical, and INR data to refine warfarin dosing.Medication-related emergency department visits and hospitalizations among older adults.Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach.Medication-related visits in a pediatric emergency department: an 8-years retrospective analysis.Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing.Medication errors in the home: a multisite study of children with cancer.Effect of education on the recording of medicines on admission to hospital.Polypharmacy in older adults: the role of the advanced practitioner in oncology.Pharmaco-miR: linking microRNAs and drug effects.Small numbers limit the use of the inpatient pediatric quality indicators for hospital comparison.Routinely recorded patient safety events in primary care: a literature review.Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: the Diabetes Study of Northern California (DISTANCE).Risk factors of self-reported adverse drug events among Medicare enrollees before and after Medicare Part D.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.Adverse drug events in the outpatient setting: an 11-year national analysisPediatric adverse drug events in the outpatient setting: an 11-year national analysis.Managing medications in clinically complex elders: "There's got to be a happy medium".Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays.Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors.An unintended consequence of electronic prescriptions: prevalence and impact of internal discrepancies.
P2860
Q26859221-1EA27BC1-04A1-4A9C-82DB-8280DE729B53Q27006081-6FBD3B07-A190-44F7-B2DA-F6ADA7059158Q27006860-42E0EDF1-5CC1-4C23-AFC5-DC8985FB9437Q27006885-0B6559BB-4569-4E8D-81E5-2C306177C376Q28109335-470F8F14-74EF-47D9-BCC8-6638DB421623Q28290501-8D1D574A-51E4-49C5-859A-6873BC670DD0Q28476135-067901BD-7C9D-49A9-8AC4-925346A807E1Q28544629-ABCB484A-4219-483C-95DB-99EBFCDABB60Q30002316-A23E2EF2-2F9E-405F-B85D-57122270E3AFQ30234897-444BD7DE-84CA-43AC-AA6D-F5FAA1E6543CQ30275196-93914C05-72F9-4613-BE76-C3057E52D345Q30394844-21353B6A-4AB8-4648-AA57-3AB53C107937Q30402433-5AE0EFAE-0D5F-474A-A982-24B1935D7CA2Q31110714-50BAAE63-9FBF-499D-A18B-00A3782CB711Q33300293-027CC20A-99DB-42B5-A734-D49518D0A069Q33311569-78E06705-A03C-47E7-A172-5A102408ABC2Q33327311-7994737C-D802-4DFD-8F5B-38B8C38DB73DQ33386953-F49ACD28-7650-4275-8C6F-0429CC02B17EQ33454254-1F55D2CC-34CD-4C24-A010-AB701430F36AQ33550741-885A5A27-E8FB-4C1E-97D2-0D5A58E9EFE4Q33715099-D332DFB8-260E-490C-9AA4-776DBEA57979Q33792583-7291B074-3BA5-4A5B-8A5D-7612EF82B63EQ33796209-F4C64890-0D4D-4154-AF66-C7234D3D7610Q33804664-4B8F22D9-B2C2-4050-990C-E46A6F45396AQ33819729-56E86F41-72EC-404F-8C00-08D67A44EC1CQ33848901-F05FD42F-CBE9-4C68-A90B-A3677DDE8132Q33885951-674358B9-92E2-46C0-8712-6D20F0E90EB7Q33920265-01F494C1-9E69-4F6E-8A40-91A35E008671Q33964943-88FA4092-3873-41A6-AC64-8FDF990324C8Q34006043-141E9FCF-A4F8-4715-ACB9-6917E1F85CB7Q34050711-A73D985C-A7B9-46D3-B1DA-2F99902CF746Q34053163-8E8975FD-8D3F-4BAA-9113-FC2B33BAE53FQ34065133-FBCA5E1A-912A-4C57-98B7-374AA0D6B985Q34096562-9887F29A-6DCD-4B2C-8208-CE2DE27592A0Q34101662-CB50755E-147F-4519-8CF0-295E117AD7FCQ34287007-FB7696CB-B764-458A-8025-ED37E8EE3518Q34311242-2C8C87AC-657E-48AE-B2E5-8B9E87E0C234Q34348637-E5395AE1-2642-4D5C-B241-DA9478CB0A6AQ34360855-453A92B8-C120-41F3-B2EB-43A3222E62E3Q34371633-724F24A6-CF04-4D68-83A7-2F85E9A7367D
P2860
National surveillance of emergency department visits for outpatient adverse drug events.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
National surveillance of emergency department visits for outpatient adverse drug events.
@ast
National surveillance of emergency department visits for outpatient adverse drug events.
@en
National surveillance of emergency department visits for outpatient adverse drug events.
@nl
type
label
National surveillance of emergency department visits for outpatient adverse drug events.
@ast
National surveillance of emergency department visits for outpatient adverse drug events.
@en
National surveillance of emergency department visits for outpatient adverse drug events.
@nl
prefLabel
National surveillance of emergency department visits for outpatient adverse drug events.
@ast
National surveillance of emergency department visits for outpatient adverse drug events.
@en
National surveillance of emergency department visits for outpatient adverse drug events.
@nl
P2093
P356
P1476
National surveillance of emergency department visits for outpatient adverse drug events.
@en
P2093
Aaron B Mendelsohn
Daniel A Pollock
Daniel S Budnitz
Joseph L Annest
Kelly N Weidenbach
Thomas J Schroeder
P304
P356
10.1001/JAMA.296.15.1858
P407
P577
2006-10-01T00:00:00Z